Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
To compare the effectiveness (efficacy, safety & tolerability) of a Single Tablet Regimen of
efavirenz/emtricitabine/tenofovir DF to subjects continuing on unmodified HAART as measured
by the proportion of patients who maintain viral load (HIV-1 RNA) <200 copies/mL at Week 48.
Phase:
Phase 4
Details
Lead Sponsor:
Gilead Sciences
Collaborator:
Bristol-Myers Squibb
Treatments:
Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Emtricitabine Tenofovir